Phase II Study of Paclitaxel, Intraperitoneal Cisplatin and IV Bevacizumab Followed by Bevacizumab Consolidation for Advanced Ovarian and Peritoneal Carcinoma
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States.
The high death rate stems from late presentation and tumor that has spread beyond the ovary
at the time of diagnoses.
Ovarian cancer typically spreads throughout the peritoneal cavity. Three randomized clinical
trial have recently demonstrated the superiority of intraperitoneal(IP) over intravenous
platinum based chemotherapy in optimally debulked advance ovarian cancer. The success of
Bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in
advanced ovarian cancer. Based on the mechanism of action of Bevacizumab, there may be
benefit of extended therapy with this agent.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluating the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
D. Scott McMeekin, MD
University of Oklahoma
United States: Food and Drug Administration
|University of Oklahoma Health Sciences Center||Oklahoma City, Oklahoma 73104|